As we see from the chart, the buying interests started from mid December last year, and the key factor related to the buying interests has not change yet: people are still waiting for DSCOD’s follow-up to FDA’s complete response letter regarding its Surfaxin, the lead drug candidate of DSCOD for the prevention of RDS in premature infants.
DSCOD only has a market cap about $48 millions. The company’s share price may rebound from here.
Conclusion: AGB just started a position on DSCOD.
Disclosure: I am long DSCO.
Additional disclosure: DSCO is currently changed to DSCOD
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.